Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma ...Middle East

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of talquetamab (JNJ-64407564) for the treatment of relapsed or refractory multiple myeloma (NCT03399799)....

Hence then, the article about janssen presents first data from the phase 1 study of the gprc5dxcd3 bispecific talquetamab in patients with relapsed or refractory multiple myeloma was published today ( Sunday 06/12/2020 - 01:46 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma )

Also on site :

• Aldi's Delightful Kitchen Mats Will Make You Feel Like You're Cooking in a Countryside Cottage
• Casting News: Task Adds Mahershala Ali, Succession Alum Joins HBO Comedy, And More
• Mahershala Ali Joins Mark Ruffalo In Season Two Of ‘Task’ At HBO